Azaphen dihydrochloride monohydrate
Based on 1 publication(s) in Google Scholar
Azaphen (Pipofezin) dihydrochloride monohydrate is an orally active serotonin reuptake inhibitor. Azaphen dihydrochloride monohydrate potentiates sympathomimetic compound effects. Azaphen dihydrochloride monohydrate can be used for the research of depressive states.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.94%
- CAS No.: 63302-99-8
- Formule: C16H23Cl2N5O2
- Masse moléculaire:388.29
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antidepressant Compound Library
HY-L108
-
EMA-Approved Drug Library
HY-L116
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Azaphen dihydrochloride monohydrate
More
Activité biologique
Azaphen (25-50 mg/kg; s.c.; single dose) dihydrochloride monohydrate significantly increases the group toxicity of Phenamine in white mice, inducing up to 95% mortality when combined with 10 mg/kg Phenamine, while also enhancing Phenamine-induced motor activity and hyperthermia[1].
Azaphen (25-50 mg/kg; s.c.; single dose) dihydrochloride monohydrate antagonizes Reserpine (HY-N0480)-induced depression effects in white mice, reducing blepharoptosis to 2.6 points and 2.3 points, respectively, while decreasing hypothermia[1].
Azaphen (25-50 mg/kg; s.c.; single dose) dihydrochloride monohydrate antagonizes Tetrabenazine (HY-B0590)-induced depression effects in white mice, reducing blepharoptosis to 2.3 points and 1.1 points, respectively, while decreasing hypothermia and catalepsy[1].
Azaphen (25 mg/kg; p.o.; single dose) dihydrochloride monohydrate significantly increases active escape attempts in the mouse water escape test, with a mean of 48 water wheel rotations per mouse over 6 minutes[2].
Azaphen (10-25 mg/kg; p.o.; single dose) dihydrochloride monohydrate exhibits antireserpine activity in mice, with a statistically significant reduction in Reserpine-induced blepharoptosis at 25 mg/kg to a rate of 2.7[2].
Azaphen (25 mg/kg; p.o.; single dose) dihydrochloride monohydrate significantly reduces anxiety-related inhibition in mice exposed to electric irritation, increasing plate crossings to 10.5 over 2 minutes[2].
Azaphen (25 mg/kg; p.o.; single dose) dihydrochloride monohydrate significantly reduces aggressive behavior in mice, decreasing fight counts to 8 (isolation-induced) and 9 (electric irritation-induced)[2].
Azaphen (10 mg/kg; p.o.; single dose) dihydrochloride monohydrate significantly reduces amnesia in rats, increasing passive avoidance conditioned reflex retention to 30% (electroshock-induced) and 50% (Scopolamine (HY-N0296)-induced)[2].
Azaphen (10 mg/kg; p.o.; daily; 4 days) dihydrochloride monohydrate does not produce a statistically significant restoration of ethanol-impaired active avoidance conditioned reflex learning in rats[2].
Azaphen (25-100 mg/kg; p.o.; single dose) dihydrochloride monohydrate exhibits dose-dependent antihypoxic activity in mice, significantly increasing survival time in hypoxic hypoxia at 50 mg/kg (37 min) and 100 mg/kg (44 min), and in hemic hypoxia at 25 mg/kg (22 min) and 50 mg/kg (21 min)[2].
Azaphen (25 mg/kg; p.o.; daily; 5 days) dihydrochloride monohydrate produces a pronounced protective effect in rats with circulatory hypoxia, resulting in 100% survival over 5 days[2].
Azaphen (5-25 mg/kg; p.o.; single dose) dihydrochloride monohydrate increases physical endurance in mice swimming with a load[2].
Azaphen (25 mg/kg; p.o.; single dose) dihydrochloride monohydrate does not produce a statistically significant change in mouse motor activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:White mice[1]
-
Dosage:25 mg/kg; 50 mg/kg
-
Administration:s.c.; single dose
-
Result:Caused 35% mortality when combined with Phenamine (5 mg/kg).
Caused 65% mortality when combined with Phenamine (5 mg/kg).
Caused 60% mortality when combined with Phenamine (10 mg/kg).
Caused 95% mortality when combined with Phenamine (10 mg/kg).
Enhanced Phenamine-induced motor activity and hyperthermia.
-
Animal Model:White mice[1]
-
Dosage:25 mg/kg; 50 mg/kg
-
Administration:s.c.; single dose
-
Result:Reduced Reserpine-induced blepharoptosis from a control of 3.7 points to 2.6 points.
Reduced Reserpine-induced blepharoptosis from a control of 3.7 points to 2.3 points.
Decreased Reserpine-induced hypothermia.
-
Animal Model:White mice[1]
-
Dosage:25 mg/kg; 50 mg/kg
-
Administration:s.c.; single dose
-
Result:Reduced Tetrabenazine-induced blepharoptosis from a control of 3.2 points to 2.3 points.
Reduced Tetrabenazine-induced blepharoptosis from a control of 3.2 points to 1.1 points.
Decreased Tetrabenazine-induced hypothermia and catalepsy.
-
Animal Model:white mice (male and female, 18-20 g)[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased the number of water wheel rotations to 48 per mouse.
-
Animal Model:white mice (male and female, 18-20 g)[2]
-
Dosage:10 mg/kg; 25 mg/kg
-
Administration:p.o.; single dose
-
Result:Resulted in a blepharoptosis rate of 3.0 per mouse at 10 mg/kg.
Resulted in a blepharoptosis rate of 2.7 per mouse at 25 mg/kg, which was statistically significant compared to control.
-
Animal Model:white mice (male and female, 18-20 g)[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased the number of plate crossings to 10.5 per mouse, a statistically significant increase compared to the irritated control group.
-
Animal Model:white mice (male, 22-25 g)[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced the number of fights to 8 in isolation-induced aggression, statistically significant compared to control.
Reduced the number of fights to 9 in electric irritation-induced aggression, statistically significant compared to control.
-
Animal Model:white mongrel rats (male, 180-200 g)[2]
-
Dosage:10 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased the percentage of rats retaining PACR from 3% to 30% in electroshock-induced amnesia, statistically significant compared to control.
Increased the percentage of rats retaining PACR from 20% to 50% in Scopolamine-induced amnesia, statistically significant compared to control.
-
Animal Model:white mongrel rats (male, 180-200 g)[2]
-
Dosage:10 mg/kg
-
Administration:p.o.; daily; 4 days
-
Result:Resulted in 2, 7, 13, and 14 AACR events over 10 runs in 10 rats on days 1-4 of training, with no statistically significant difference compared to the ethanol-only control group.
-
Animal Model:white mice (male and female, 18-20 g)[2]
-
Dosage:25 mg/kg; 50 mg/kg; 100 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased survival time to 34 min in hypoxic hypoxia at 25 mg/kg.
Increased survival time to 37 min in hypoxic hypoxia at 50 mg/kg, statistically significant.
Increased survival time to 44 min in hypoxic hypoxia at 100 mg/kg, statistically significant.
Increased survival time to 22 min in hemic hypoxia at 25 mg/kg, statistically significant.
Increased survival time to 21 min in hemic hypoxia at 50 mg/kg, statistically significant.
-
Animal Model:white mongrel rats (male, 180-200 g)[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; daily; 5 days
-
Result:Resulted in 100% survival on both day 1 and day 5 post-ligation, a statistically significant increase compared to control.
-
Animal Model:white mice (male and female, 18-20 g)[2]
-
Dosage:5 mg/kg; 10 mg/kg; 25 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased swimming duration to 8.3 min at 5 mg/kg, statistically significant.
Increased swimming duration to 11.8 min at 10 mg/kg, statistically significant.
Increased swimming duration to 12.1 min at 25 mg/kg, statistically significant.
-
Animal Model:white mice[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; single dose
-
Result:Resulted in 508 runs per group of 3 mice, with no statistically significant difference compared to control.
Chemical Information
-
CAS No. 63302-99-8
-
Appearance Solid
-
Masse moléculaire 388.29
-
Formule C16H23Cl2N5O2
-
Color Light yellow to green yellow
-
SMILES
[H]Cl.[H]Cl.CN1C2=CC=CC=C2OC3=C1C=C(N4CCN(C)CC4)N=N3.O
-
Synonyms
Azafen dihydrochloride monohydrate; Pipofezin dihydrochloride monohydrate; Pipofezine dihydrochloride monohydrate; Azaphenonxazine dihydrochloride monohydrate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biochim Biophys Acta Gen Subj
5-Hydroxytryptamine activates a 5-HT/c-Myc/SLC6A4 signaling loop in non-small cell lung cancer. [Abstract]2022 Apr;1866(4):130093. PMID: 35066124
Solvant et solubilité
H2O : ≥ 100 mg/mL (257.54 mM)
DMSO : 1 mg/mL (2.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (128.77 mM); Clear solution; Need ultrasonic
Pureté et documentation
-
Fiche technique (287 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 2.5754 mL | 12.8770 mL | 25.7539 mL | 64.3849 mL |
| H2O | 5 mM | 0.5151 mL | 2.5754 mL | 5.1508 mL | 12.8770 mL |
| 10 mM | 0.2575 mL | 1.2877 mL | 2.5754 mL | 6.4385 mL | |
| 15 mM | 0.1717 mL | 0.8585 mL | 1.7169 mL | 4.2923 mL | |
| 20 mM | 0.1288 mL | 0.6438 mL | 1.2877 mL | 3.2192 mL | |
| 25 mM | 0.1030 mL | 0.5151 mL | 1.0302 mL | 2.5754 mL | |
| 30 mM | 0.0858 mL | 0.4292 mL | 0.8585 mL | 2.1462 mL | |
| 40 mM | 0.0644 mL | 0.3219 mL | 0.6438 mL | 1.6096 mL | |
| 50 mM | 0.0515 mL | 0.2575 mL | 0.5151 mL | 1.2877 mL | |
| 60 mM | 0.0429 mL | 0.2146 mL | 0.4292 mL | 1.0731 mL | |
| 80 mM | 0.0322 mL | 0.1610 mL | 0.3219 mL | 0.8048 mL | |
| 100 mM | 0.0258 mL | 0.1288 mL | 0.2575 mL | 0.6438 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Azaphen dihydrochloride monohydrate Related Classifications
HY-A0022A Related Classifications
Powered by Bioz